ALGS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ALGS is not a good buy right now for a beginner long-term investor, even with $50,000-$100,000 available. The stock has a bearish technical setup, no strong proprietary buy signal, and the business is still loss-making with cash runway limited into Q4 2026. While the recent revenue growth, analyst Buy ratings, and licensing catalyst are positive, the current setup is better viewed as a speculative hold/watch rather than an immediate long-term buy.
The technical picture is weak. MACD histogram is negative and worsening, RSI_6 at 33.963 is near oversold but not a clear reversal signal, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price at 6.03 sits just above support at 5.977 and below pivot 6.302, so momentum remains fragile. The modeled trend also suggests downside over the next week and month, which argues against buying immediately.
Recent catalysts are constructive: Q1 revenue rose 812.9% year over year to $2.83M and beat expectations, EPS beat by $0.04, hedge funds have been buying with a 162.30% increase in buying activity last quarter, and the company expects a $25M upfront payment from the Amoytop Greater China licensing deal. Analysts also see the stock as inexpensive relative to cash and note potential differentiation in the hepatitis B program.
Technical momentum is bearish, no AI Stock Picker or SwingMax signal is present, and similar-pattern trend analysis points to weakness over the next week and month. Insider activity is neutral, congress trading data is absent, and the recent market action was mixed with regular-session weakness despite post-market strength.
In Q1 2026, Aligos delivered strong top-line growth with revenue of $2.83M, up about 810%-813% year over year, and beat estimates materially. However, profitability remains poor: net income was -$23.04M and gross margin was 0, showing the company is still in a pre-commercial, cash-burn phase. The latest quarter was Q1 2026.
Wall Street sentiment is bullish but cautious. WestPark Capital initiated coverage with a Buy and $48 target, and Jefferies also started Buy coverage but cut its target to $48 from $60, saying the shares look inexpensive and the setup is asymmetric ahead of a 2027 Phase II readout. The pros view is that the stock is near cash value with meaningful upside if the hepatitis B asset works; the cons view is that it is still highly execution-dependent, data is far away, and the target was reduced from prior levels.
